Immix Biopharma (IMMX) Competitors $2.72 +0.01 (+0.37%) Closing price 04:00 PM EasternExtended Trading$2.72 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMMX vs. AARD, BNTC, HRTX, AVIR, SGMT, MREO, NMRA, SCPH, MNPR, and EDITShould you be buying Immix Biopharma stock or one of its competitors? The main competitors of Immix Biopharma include Aardvark Therapeutics (AARD), Benitec Biopharma (BNTC), Heron Therapeutics (HRTX), Atea Pharmaceuticals (AVIR), Sagimet Biosciences (SGMT), Mereo BioPharma Group (MREO), Neumora Therapeutics (NMRA), scPharmaceuticals (SCPH), Monopar Therapeutics (MNPR), and Editas Medicine (EDIT). These companies are all part of the "pharmaceutical products" industry. Immix Biopharma vs. Its Competitors Aardvark Therapeutics Benitec Biopharma Heron Therapeutics Atea Pharmaceuticals Sagimet Biosciences Mereo BioPharma Group Neumora Therapeutics scPharmaceuticals Monopar Therapeutics Editas Medicine Immix Biopharma (NASDAQ:IMMX) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation. Do insiders & institutionals have more ownership in IMMX or AARD? 11.3% of Immix Biopharma shares are owned by institutional investors. 55.4% of Immix Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts rate IMMX or AARD? Immix Biopharma presently has a consensus price target of $7.00, indicating a potential upside of 157.35%. Aardvark Therapeutics has a consensus price target of $33.00, indicating a potential upside of 143.00%. Given Immix Biopharma's higher possible upside, analysts clearly believe Immix Biopharma is more favorable than Aardvark Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immix Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Aardvark Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is IMMX or AARD more profitable? Aardvark Therapeutics' return on equity of 0.00% beat Immix Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Immix BiopharmaN/A -130.02% -86.33% Aardvark Therapeutics N/A N/A N/A Does the media prefer IMMX or AARD? In the previous week, Aardvark Therapeutics had 2 more articles in the media than Immix Biopharma. MarketBeat recorded 3 mentions for Aardvark Therapeutics and 1 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 1.89 beat Aardvark Therapeutics' score of 0.96 indicating that Immix Biopharma is being referred to more favorably in the media. Company Overall Sentiment Immix Biopharma Very Positive Aardvark Therapeutics Positive Which has preferable earnings and valuation, IMMX or AARD? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmix BiopharmaN/AN/A-$21.61M-$0.70-3.89Aardvark TherapeuticsN/AN/A-$20.59MN/AN/A SummaryAardvark Therapeutics beats Immix Biopharma on 5 of the 9 factors compared between the two stocks. Get Immix Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMMX vs. The Competition Export to ExcelMetricImmix BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$75.83M$3.01B$5.71B$9.54BDividend YieldN/A2.37%4.70%4.05%P/E Ratio-3.8921.6328.2220.09Price / SalesN/A332.55470.71102.59Price / CashN/A41.5825.1828.40Price / Book5.678.178.465.80Net Income-$21.61M-$55.06M$3.25B$259.32M7 Day Performance-9.03%4.48%2.72%1.42%1 Month Performance25.35%18.40%10.78%11.84%1 Year Performance21.43%3.05%34.15%17.00% Immix Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMMXImmix Biopharma3.7984 of 5 stars$2.72+0.4%$7.00+157.4%+21.0%$75.83MN/A-3.899AARDAardvark TherapeuticsN/A$14.16+3.0%$33.00+133.1%N/A$307.27MN/A0.0018BNTCBenitec Biopharma1.588 of 5 stars$11.55+2.5%$26.00+125.2%+18.9%$303.21M$80K-7.6520HRTXHeron Therapeutics3.7851 of 5 stars$1.96+2.9%$5.00+155.8%-37.4%$298.26M$144.29M-32.58300Positive NewsAVIRAtea Pharmaceuticals2.4408 of 5 stars$3.45+0.4%$6.00+74.2%-0.5%$294.82MN/A-2.0970Positive NewsSGMTSagimet Biosciences2.6683 of 5 stars$9.57-0.4%$26.60+178.1%+199.4%$293.97M$2M-5.458Gap DownMREOMereo BioPharma Group1.7681 of 5 stars$1.83+3.7%$7.20+294.5%-57.6%$290.18M$10M-26.0740NMRANeumora Therapeutics2.4215 of 5 stars$1.77-6.6%$7.14+304.7%-81.8%$287.91MN/A-1.11108SCPHscPharmaceuticals4.3622 of 5 stars$5.41+0.5%$14.00+159.0%+13.4%$285.54M$36.33M-2.8330Positive NewsMNPRMonopar Therapeutics2.2425 of 5 stars$46.73+3.3%$60.00+28.4%+1,149.2%$285.45MN/A-13.4110EDITEditas Medicine4.0772 of 5 stars$3.43+1.9%$4.70+37.2%-44.2%$285.12M$32.31M-1.12230Analyst Upgrade Related Companies and Tools Related Companies Aardvark Therapeutics Competitors Benitec Biopharma Competitors Heron Therapeutics Competitors Atea Pharmaceuticals Competitors Sagimet Biosciences Competitors Mereo BioPharma Group Competitors Neumora Therapeutics Competitors scPharmaceuticals Competitors Monopar Therapeutics Competitors Editas Medicine Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMMX) was last updated on 7/28/2025 by MarketBeat.com Staff From Our PartnersOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTop 10 Green Zone Stocks to Buy NowOthers have paid $2,000 for access to stock picks like these—this weekend, you can get them free. Using a p...TradeSmith | SponsoredTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trill...Stansberry Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immix Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immix Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
